Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 22, 2026, 6:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–16 of 16 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Vilazodone 40 mg Clear all
Completed Phase 4 Interventional

Vilazodone for the Treatment of Posttraumatic Stress Disorder

NCT01715519
View directory record Official record
Conditions
PTSD, Depression
Interventions
Treatment (Viibryd)
Drug
Lead sponsor
Southern California Institute for Research and Education
Other
Eligibility
18 Years to 55 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
2
States / cities
Long Beach, California • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 24, 2017 · Synced Sep 22, 2026, 6:45 AM EDT
Suspended Phase 2 Interventional Accepts healthy volunteers

Department of Defense PTSD Adaptive Platform Trial - Master Protocol

NCT05422612
View directory record Official record
Conditions
Post Traumatic Stress Disorder
Interventions
Intervention A Fluoxetine Hydrochloride (HCl), Intervention A Placebo, Intervention B Vilazodone Hydrochloride (HCl), Intervention B Placebo, Intervention C Daridorexant, Intervention C Placebo, Intervention D SLS-002, Intervention D Placebo
Drug
Lead sponsor
Global Coalition for Adaptive Research
Other
Eligibility
18 Years to 65 Years
Enrollment
800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2029
U.S. locations
9
States / cities
Miami, Florida • Atlanta, Georgia • Tripler AMC, Hawaii + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 22, 2026, 6:45 AM EDT
Completed Phase 3 Interventional Results available

Safety, Efficacy and Tolerability of Vilazodone in Patients With Generalized Anxiety Disorder

NCT01766401
View directory record Official record
Conditions
Generalized Anxiety Disorder
Interventions
Placebo, Vilazadone
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 70 Years
Enrollment
402 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
30
States / cities
Arcadia, California • Beverly Hills, California • Encino, California + 26 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Sep 22, 2026, 6:45 AM EDT
Completed Not applicable Interventional Results available

Vilazodone for Menopausal Hot Flashes

NCT01680900
View directory record Official record
Conditions
Hot Flushes
Interventions
vilazodone, placebo capsules
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
45 Years to 60 Years · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 13, 2015 · Synced Sep 22, 2026, 6:45 AM EDT
Completed Phase 4 Interventional

Safety and Efficacy of Vilazodone in Major Depressive Disorder

NCT01573598
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Placebo, Vilazodone
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 70 Years
Enrollment
1,219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
38
States / cities
Beverly Hills, California • Chino, California • Costa Mesa, California + 32 more
Source: ClinicalTrials.gov public record
Updated May 17, 2015 · Synced Sep 22, 2026, 6:45 AM EDT
Completed Phase 4 Interventional Results available

Safety, Efficacy, and Tolerability of Vilazodone in Major Depressive Disorder

NCT01473394
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Dose-matched placebo, Vilazodone
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 70 Years
Enrollment
518 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
14
States / cities
Beverly Hills, California • Encino, California • New Port Beach, California + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2014 · Synced Sep 22, 2026, 6:45 AM EDT
Withdrawn Phase 4 Interventional

The Effects of Vilazodone on Glutamate in the Anterior Cingulate Cortex in Anxious Unipolar Depressives

NCT02028026
View directory record Official record
Conditions
Major Depressive Disorder, Anxiety, Comorbidity
Interventions
Vilazodone, Citalopram
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 50 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 7, 2016 · Synced Sep 22, 2026, 6:45 AM EDT
Completed Phase 3 Interventional Results available

A One Year Open Label Study Assessing the Safety and Tolerability of Vilazodone in Patients With Major Depressive Disorder (MDD)

NCT00644358
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
vilazodone
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 70 Years
Enrollment
616 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
38
States / cities
Garden Grove, California • San Diego, California • Torrance, California + 34 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2017 · Synced Sep 22, 2026, 6:45 AM EDT
Completed Phase 3 Interventional Results available

Randomized, Double-Blind, Placebo Controlled Study of Vilazodone's Efficacy, Safety, and Biomarkers of Response in Major Depressive Disorder (MDD)

NCT00683592
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
vilazodone, placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 70 Years
Enrollment
481 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
9
States / cities
Newport Beach, California • Bradenton, Florida • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2010 · Synced Sep 22, 2026, 6:45 AM EDT
Completed Phase 3 Interventional Results available

Safety, Efficacy and Tolerability of Vilazodone in (GAD) Generalized Anxiety Disorder

NCT01844115
View directory record Official record
Conditions
Generalized Anxiety Disorder
Interventions
Placebo, Vilazodone
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 70 Years
Enrollment
415 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
36
States / cities
Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 29 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Sep 22, 2026, 6:45 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Vilazodone for Corticosteroid-Induced Memory Impairment

NCT01828515
View directory record Official record
Conditions
Memory Impairment
Interventions
Vilazodone, Placebo, Hydrocortisone
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 10, 2019 · Synced Sep 22, 2026, 6:45 AM EDT
Completed Phase 3 Interventional Results available

Switching From Generic Selective Serotonin Reuptake Inhibitors (SSRIs) and Selective Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) to Three Different Dose Initiation Strategies With Vilazodone

NCT02015546
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
Vilazodone
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 15, 2015 · Synced Sep 22, 2026, 6:45 AM EDT
Completed Phase 2 Interventional Results available

Vilazodone Treatment for Marijuana Dependence

NCT01574183
View directory record Official record
Conditions
Marijuana Dependence
Interventions
Vilazodone, Placebo
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 9, 2016 · Synced Sep 22, 2026, 6:45 AM EDT
Completed Phase 4 Interventional Results available

Safety and Efficacy of Vilazodone in Major Depressive Disorder

NCT01473381
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Vilazodone, Placebo to citalopram, Placebo to vilazodone, Citalopram
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 70 Years
Enrollment
1,162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
54
States / cities
Birmingham, Alabama • Dothan, Alabama • Scottsdale, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2014 · Synced Sep 22, 2026, 6:45 AM EDT
Completed Phase 2 Interventional Results available

A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy

NCT03321526
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
JNJ-42847922, Placebo Matching to JNJ-42847922, Quetiapine XR, Placebo Matching to Quetiapine XR, Selective Serotonin Reuptake Inhibitor (SSRI), Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
50
States / cities
Phoenix, Arizona • Tempe, Arizona • Rogers, Arkansas + 41 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 22, 2026, 6:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Sexual Functioning of Healthy Adults After Receiving Vilazodone, Paroxetine or Placebo

NCT02097147
View directory record Official record
Conditions
Healthy
Interventions
Vilazodone 20 mg, Vilazodone 40 mg, Paroxetine 20 mg, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
202 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
4
States / cities
Miami, Florida • Overland Park, Kansas • Saint Paul, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2015 · Synced Sep 22, 2026, 6:45 AM EDT